Search research articles
Contact Us
Filters
Showing results (111-120 of 231) with videos related to
Page
of 24
Sort By:
Blood Advances
|
December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
American Journal of Hematology
|
January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Evangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Blood
|
September 28, 2013
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Bruno Paiva, Teresa Paino, Jose-Maria Sayagues, et al.
The Lancet. Oncology
|
June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Leukemia Research Reports
|
October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Aurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 231) with videos related to
Sort By:
Page
of 24
Blood Advances
|
December 4, 2023
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, et al.
American Journal of Hematology
|
January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Evangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Blood
|
September 28, 2013
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Bruno Paiva, Teresa Paino, Jose-Maria Sayagues, et al.
The Lancet. Oncology
|
June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
British Journal of Haematology
|
July 6, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Advances in Therapy
|
March 24, 2023
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Philippe Moreau, Niels W C J van de Donk, Michel Delforge, et al.
Leukemia Research Reports
|
October 27, 2015
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Aurelio Lopez, Maria-Victoria Mateos, Albert Oriol, et al.
Haematologica
|
December 22, 2022
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Maria-Victoria Mateos, Katja Weisel, Thomas Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2011
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
Bruno Paiva, Joaquin Martinez-Lopez, Maria-Belen Vidriales, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, et al.
Page
of 24